Johnson & Johnson Q3 sales rise on MedTech growth, lifts 2026 outlook

By Reuters News


Overview

  • US healthcare conglomerate's Q3 sales rose 5.9%, slightly beating analyst expectations

  • Adjusted EPS for Q3 was $2.59, beating analyst expectations

  • Company raised 2026 sales and adjusted EPS guidance


Outlook

  • Johnson & Johnson raises 2026 reported sales guidance to $101.2 bln at midpoint

  • Company increases 2026 adjusted EPS guidance to $11.10 at midpoint

  • Johnson & Johnson sees 2026 reported sales growth of 7.4% at midpoint


Result Drivers

  • PRODUCT LAUNCHES AND ONCOLOGY GROWTH - Co said sales growth was driven by new products in Immunology and strong performance in Oncology and Neuroscience

  • MEDTECH SALES - MedTech sales growth was led by cardiovascular electrophysiology products, contact lenses, and orthopaedics trauma

  • SPECIAL CHARGES - Q3 EPS was reduced by one-time charges related to talc litigation, Firefly Bio acquisition, and Sail Biomedicines collaboration


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Slight Beat*

$25.40 bln

$25.28 bln (16 Analysts)

Q3 Adjusted EPS

Beat

$2.59

$2.54 (16 Analysts)

Q3 EPS

$0.09

Q3 Net Income

$210 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for Johnson & Johnson is $282.00, about 6.9% above its October 12 closing price of $263.73

  • The stock recently traded at 22 times the next 12-month earnings vs. a P/E of 21 three months ago


Reuters Recommended Reads

  • Oct 12 - Bristol Myers radiopharma cancer drug slows rare tumor progression in study

  • Oct 13 - UnitedHealth Q3 revenue beats; raises profit forecast


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.